ENZ Enzo Biochem Dashboard

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Company profile

Ticker

ENZ

Exchange

NYSE

Website

www.enzo.com

CEO

Elazar Rabbani

Incorporated

New York

Location

New York

Fiscal year end

Jul 31

Sector

Professional, Scientific, and Technical Services > Testing Laboratories

Industry (SIC)

Services - Medical Laboratories

Quest Diagnostics • Laboratory Corp. Of America • Radnet • Burning Rock Biotech • Guardant Health • Genomic Health • Invitae • Natera • Progenity • Centogene ...

SEC CIK

0000316253

Corporate docs

Articles of Incorporation & Bylaws

IRS number

132866202

ENZ stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

FDA Expands EUA For Rapid Extraction On One COVID-19 Test System

20 Jul 21

Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Jul. 20, 2021: NFLX, SFTW, AEHR, LCAP, ENZ

20 Jul 21

Today's 5 Stock Ideas: Netflix (NFLX) - Will report Q2 earnings after market close on Tuesday. Analysts expect earnings of $3.15 per share on sales around $7.32 billion. The company has historically

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

20 Jul 21

Enzo Biochem Reports FDA Emergency Use Authorization For Rapid Extraction Method On Proprietary Test System For Detection Of Coronavirus SARS-CoV-2

20 Jul 21

Enzo Biochem On June 14, Received Notification That Sba Rendered Final Decision Regarding Its Review Of Co.'s PPP Loan Forgiveness Application

14 Jun 21

Press releases

Pro users get this 30m faster

ENZO BIOCHEM RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR RAPID EXTRACTION METHOD ON PROPRIETARY TEST SYSTEM FOR DETECTION OF CORONAVIRUS SARS-CoV-2

20 Jul 21

NEW YORK, NY, July 20, 2021 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE:ENZ) ("Enzo" or the "Company"), a leading biosciences and diagnostics company, announced today that it has received an expansion of its FDA

Enzo Biochem Announces Online Service with TrustAssure to Schedule Timely PCR Testing Required for International Travel

15 Jun 21

Testing will be available through CLX Health's TrustAssure™ Global Testing Platform for international travelers from New York and New Jersey who will need to complete testing immediately prior to travel.

Enzo Biochem Reports Third Quarter Fiscal 2021 Results

9 Jun 21

Total third quarter revenue of $32.8 million, a record quarterly high, increased 94% year-over-year Consolidated quarterly gross margin was 49% versus 26% in the previous year period, confirming Enzo's vertically

Enzo Biochem to Report Third Quarter 2021 Financial Results on Wednesday, June 9

1 Jun 21

Calendar

11 Jun 21

30 Jul 21

31 Jul 21

Financial summary

Financial statements Chart ENZ financial data

Quarter (USD)	Apr 21	Jan 21	Oct 20	Jul 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Jul 20	Jul 19	Jul 18	Jul 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	15.84M	15.84M	15.84M	15.84M	15.84M	15.84M
Cash burn (monthly)	9.82M	3.28M	(positive/no burn)	(positive/no burn)	(positive/no burn)	398.5K
Cash used (since last report)	29.77M	9.94M	n/a	n/a	n/a	1.21M
Cash remaining	-13.93M	5.9M	n/a	n/a	n/a	14.63M
Runway (months of cash)	-1.4	1.8	n/a	n/a	n/a	36.7

Beta Read what these cash burn values mean

Recent insider trades

ENZ insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Mar 21	Harbert Management	Common Stock	Sell	Dispose S	Yes	No	4.539	100,000	453.9K	5,175,913
16 Mar 21	Harbert Management	Common Stock	Sell	Dispose S	Yes	No	4.7	200,000	940K	5,275,913
15 Mar 21	Harbert Management	Common Stock	Sell	Dispose S	Yes	No	5	44,768	223.84K	5,475,913
15 Mar 21	Harbert Management	Common Stock, $0.01 par value ("Common Stock")	Sell	Dispose S	Yes	No	4.75	100,000	475K	5,520,681
11 Jan 21	Ian B. Walters	Stock Option (to acquire Common Stock) Common Stock	Grant	Aquire A	No	No	2.63	77,101	202.78K	77,101
11 Jan 21	David Bench	Stock Option (to acquire Common Stock) Common Stock	Grant	Aquire A	No	No	2.63	55,400	145.7K	110,800
11 Jan 21	Elazar Rabbani	Common Stock, par value $0.01 per share	Grant	Aquire A	No	No	0	190,114	0	2,262,208
11 Jan 21	Perlysky Dov	Stock Option (to acquire Common Stock) Common Stock	Grant	Aquire A	No	No	2.63	77,101	202.78K	335,780

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

ENZ institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

67.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	81	83	-2.4%
Opened positions	9	7	+28.6%
Closed positions	11	7	+57.1%
Increased positions	17	24	-29.2%
Reduced positions	34	24	+41.7%

13F shares	Current	Prev Q	Change
Total value	177.23M	108.89M	+62.8%
Total shares	32.64M	34.9M	-6.5%
Total puts	300.7K	163K	+84.5%
Total calls	70.7K	53.5K	+32.1%
Total put/call ratio	4.3	3.0	+39.6%

Largest owners	Shares	Value	Change
Harbert Fund Advisors	5.18M	$17.81M	-7.9%
Harbert Discovery Fund	5.18M	$21.12M	-7.9%
BLK Blackrock	3.91M	$13.45M	+4.1%
Renaissance Technologies	3.34M	$11.49M	-6.1%
Roumell Asset Management	2.74M	$9.41M	-1.2%
Evermore Global Advisors	2.61M	$8.96M	0.0%
Vanguard	2.39M	$8.21M	-0.5%
Dimensional Fund Advisors	1.63M	$5.62M	-4.1%
STT State Street	798.32K	$2.75M	-5.8%
Geode Capital Management	660.03K	$2.27M	+10.2%

Largest transactions	Shares	Bought/sold	Change
Ariel Investments	237.99K	-633.12K	-72.7%
Harbert Fund Advisors	5.18M	-444.77K	-7.9%
Harbert Discovery Fund	5.18M	-444.77K	-7.9%
Renaissance Technologies	3.34M	-215.36K	-6.1%
VIEX Capital Advisors	0	-155.48K	EXIT
BLK Blackrock	3.91M	+153.24K	+4.1%
Panagora Asset Management	58.92K	-133.65K	-69.4%
Corsair Capital Management	0	-116.25K	EXIT
Group One Trading	239.27K	+99.14K	+70.8%
WFC Wells Fargo & Co.	23.3K	-92.85K	-79.9%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: ahead, bond, discretion, ETF, Europe, geographic, headcount, hold, infection, judice, kit, municipal, mutual, refiled, reply, sixteen, slightly, Spending, tempered, unrealized, vaccinated, yield

Removed: accrue, case, continued, franc, intention, investable, professional, receiving, strain, Suspending, unrecouped, unvested

From filing 10-Q 2021 Q3